.png){kind=logo}
Owning stocks is exciting, but the excitement rarely lasts long without much effort. The market has rebounded from a volatile period, so there is no better time to buy or hold its strong performers. Here are three of the top picks for stocks that can represent great long-term growth and be some of the stocks to own: Chubb (CB), United Therapeutics (UTHR), and Freshpet (FRPT).
Chubb and Warren Buffett's Berkshire Hathaway are some other examples of insurance giants that appear pretty resilient and one great buy-and-hold stock. It earns a good IBD Composite Rating of 92 speaking of solid fundamentals and performance. Chubb's revenues have grown by 17% over two recent quarters. Its average earnings growth also reached 57% over the last three quarters.
Wall Street estimates EPS growth of 9% in 2025. The company has 6.34% equity, and its market value is $6.9 billion. It has a very positive steadiness of institutional support, with an Accumulation/Distribution Rating of B-.
Chubb is a good investment for investors wanting stability and growth prospects. Berkshire Hathaway heavily supports it, and the growth metrics are stable. Thus, it can provide security and long-term rewards.
United Therapeutics is a biotech leader in rare diseases, especially pulmonary hypertension. It is in a buy zone above its consolidation entry at 366.08, a super second-stage base pattern that investors should consider. UTHR has a composite rating of 98, and the stock is up 68% year to date, 2024.
The past three quarters have shown an EPS growth of an average of 34%, above the 25% required to be in the growth category. Projected EPS growth stands at 24% for the year, and strong institutional support continues, with shares held by funds at a level of 68%, which has indicated investor confidence.
United Therapeutics is a strong momentum stock, given the great earnings and institutional confidence assigned to it. For healthcare and biotech-enthusiastic investors, this stock represents huge money-making opportunities in the long term.
Freshpet makes "fresh" pet food, one of the highest-quality kinds, and caters to a trend pet owners want: natural pet choices. The stock has risen 65% this year, above the S&P 500, and still trades above the key buy point of 136.35, which puts it within the top 5% over the past year in terms of price.
The company experienced a modest increase in earnings. As of analysts, what the institution investors have so far harvested from this includes a loss of 62 cents in 2023 and earning 73 cents in 2024. Institutional investors have immensely garnered since funds own a higher share of it at 75%.
Freshpet, having focused on fresh pet food, proves to be an excellent long-term investment since investors are interested in a booming pet industry and their strong performance the year prior.
These are Chubb, United Therapeutics, and Freshpet stocks that offer different reasons to hold for the long term. Whether it is stable earnings for Chubb, great growth for United Therapeutics, or innovative products by Freshpet, each stands alone in its particular industry. Keep these three on the radar as the chart's next investment move.
